MedPath

The Role of 18F-FDG-PET for Staging and Prognostication

Active, not recruiting
Conditions
Mantle Cell Lymphoma
Registration Number
NCT04600804
Lead Sponsor
Fondazione Italiana Linfomi - ETS
Brief Summary

A retrospective, multicenter, non-interventional, imaging study ancillary to FIL_MCL0208 clinical trial (NCT02354313) in untreated adult patients with mantle cell lymphoma.

Detailed Description

This is a retrospective, multicenter, non-interventional, imaging study devoted to patients diagnosed with MCL and enrolled in the MCL0208 international randomized, phase III clinical trial (NCT02354313).

The study is aimed at addressing a number of prognostic issues that still need to be clarified in MCL patients, by taking advantage of the PET performed within the MCL0208 trial and available for the analysis, and the clinical records and molecular data generated in the context of the trial.

In the clinical trial PET was optional at baseline (b-PET), before ASCT (i-PET) and after-ASCT (eot-PET), and none of the exams was used in the decisionmaking strategy. All the PETs available will be collected and considered for analysis. The study will not require additional treatment or procedures except those required for the MCL0208 trial. The participation of the patient to the MCL0208 trial is a pre-requisite to be involved in this study.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Enrollment of the patient in the MCL0208 clinical trial documented by the signature of the study informed consent;
  • Patient's treatment in one of the centers that participated in the MCL0208 trial and that has joined the MCL0208-PET study as well;
  • Evidence of signed informed consent for the MCL0208-PET study.
Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Sensitivity (proportion) and agreement (Cohen K) of PET results (performed in different time points) compared to the current standard (TC plus bone marrow biopsy).24 months

To better define the role of PET for the staging of MCL patients at the time of diagnosis, for evaluation of response after induction treatment (pre-ASCT; i-PET) and post ASCT (eot-PET) in comparison to the current standards, namely computed axial tomography (CT) and bone marrow biopsy.

C-index, estimated comparing models adding or not PET parameters to standard prognostic factors in predicting PFS.24months

To build a new prognostic model for PFS, including PET parameters, MIPI-b and biological data (e.g. MRD, GEP and mutational parameters).The achievement of these objectives could help to plan futures studies in order to improve the outcome of MCL patients.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (34)

Ematologia Ospedale Maggiore Policlinico - Fondazione IRCCS Ca Granda

๐Ÿ‡ฎ๐Ÿ‡น

Milano, Lombardia, Italy

Unitร  Linfomi - Dipartimento Oncoematologia - Istituto Scientifico San Raffaele

๐Ÿ‡ฎ๐Ÿ‡น

Milano, Milan, Italy

U.O. Ematologia AOU Integrata di Verona

๐Ÿ‡ฎ๐Ÿ‡น

Verona, Veneto, Italy

Ematologia - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)

๐Ÿ‡ฎ๐Ÿ‡น

Meldola, Italy

S.C. Oncoematologia A.O. S. Maria di Terni

๐Ÿ‡ฎ๐Ÿ‡น

Terni, Umbria, Italy

Ematologia Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l Oncologia

๐Ÿ‡ฎ๐Ÿ‡น

Genova, Liguria, Italy

S.C. di Ematologia e Trapianto di Midollo Osseo A.O. S. Croce e Carle

๐Ÿ‡ฎ๐Ÿ‡น

Cuneo, Piedmont, Italy

Ematologia Universitaria A.O.U. Citta della Salute e della Scienza di Torino

๐Ÿ‡ฎ๐Ÿ‡น

Turin, Piedmont, Italy

Divisione di Ematologia A.O. Ospedali Riuniti Villa Sofia-Cervello

๐Ÿ‡ฎ๐Ÿ‡น

Palermo, Sicily, Italy

Unitะฐ funzionale di Ematologia Azienda Ospedaliera Universitaria Careggi

๐Ÿ‡ฎ๐Ÿ‡น

Firenze, Tuscany, Italy

S.C. Ematologia A.O. SS. Antonio e Biagio e Cesare Arrigo

๐Ÿ‡ฎ๐Ÿ‡น

Alessandria, Piedmont, Italy

Instituto Portuguรชs de Oncologia de Lisboa

๐Ÿ‡ต๐Ÿ‡น

Lisboa, Portugal

U.O. Clinica Ematologica Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l Oncologia

๐Ÿ‡ฎ๐Ÿ‡น

Genova, Liguria, Italy

SCDU Ematologia AOU Maggiore della Caritะฐ di Novara

๐Ÿ‡ฎ๐Ÿ‡น

Novara, Piedmont, Italy

SC Ematologia e CTMO Ospedale Businco

๐Ÿ‡ฎ๐Ÿ‡น

Cagliari, Sardinia, Italy

U.O. di Ematologia Ospedale degli Infermi di Rimini

๐Ÿ‡ฎ๐Ÿ‡น

Rimini, Emilia Romagna, Italy

S.O.C. Oncologia Medica A Centro Riferimento Oncologico

๐Ÿ‡ฎ๐Ÿ‡น

Aviano, Friuli Venezia Giulia, Italy

Ematologia Azienda Unitะฐ Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova

๐Ÿ‡ฎ๐Ÿ‡น

Reggio Emilia, Emilia Romagna, Italy

U.O.Ematologia Ospedale Guglielmo da Saliceto

๐Ÿ‡ฎ๐Ÿ‡น

Piacenza, Emilia Romagna, Italy

SOC Clinica Ematologica Azienda Sanitaria Universitaria Friuli Centrale (ASU FC)

๐Ÿ‡ฎ๐Ÿ‡น

Udine, Friuli Venezia Giulia, Italy

Ematologia Universitะฐ Cattolica S. Cuore

๐Ÿ‡ฎ๐Ÿ‡น

Roma, Latium, Italy

SC Ematologia ASST Grande Ospedale Metropolitano Niguarda

๐Ÿ‡ฎ๐Ÿ‡น

Milano, Lombardia, Italy

Div. di Ematologia IRCCS Policlinico S. Matteo di Pavia

๐Ÿ‡ฎ๐Ÿ‡น

Pavia, Lombardia, Italy

Ematologia ASST MONZA Ospedale S. Gerardo

๐Ÿ‡ฎ๐Ÿ‡น

Monza, Lombardia, Italy

U.O. Ematologia Istituto Clinico Humanitas

๐Ÿ‡ฎ๐Ÿ‡น

Rozzano, Lombardia, Italy

Ematologia Ospedale Vito Fazzi

๐Ÿ‡ฎ๐Ÿ‡น

Lecce, Puglia, Italy

U.O.C Ematologia e Trapianto A.O. C. Panico

๐Ÿ‡ฎ๐Ÿ‡น

Tricase, Puglia, Italy

Divisione di Ematologia e T.M.O. - Ospedale Centrale di Bolzano

๐Ÿ‡ฎ๐Ÿ‡น

Bolzano, Trentino Alto Adige, Italy

S.C di Ematologia Ospedale Ca Foncello

๐Ÿ‡ฎ๐Ÿ‡น

Treviso, Veneto, Italy

U.O. Ematologia - AOU Pisana

๐Ÿ‡ฎ๐Ÿ‡น

Pisa, Italy

Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI)

๐Ÿ‡ฎ๐Ÿ‡น

Trieste, Italy

Ematologia ASST Spedali Civili di Brescia

๐Ÿ‡ฎ๐Ÿ‡น

Brescia, Lombardy, Italy

S.C.Ematologia A.O.U. Citta della Salute e della Scienza di Torino

๐Ÿ‡ฎ๐Ÿ‡น

Turin, Piedmont, Italy

S.C. Ematologia Azienda Ospedali Riuniti Papardo-Piemonte

๐Ÿ‡ฎ๐Ÿ‡น

Messina, Sicily, Italy

ยฉ Copyright 2025. All Rights Reserved by MedPath